Boehringer Ingelheim Expands Oncology Pipeline via Strategic Collaboration with Tempus AI

Boehringer Ingelheim and Tempus AI have entered a multi-year strategic partnership to enhance Boehringer's oncology drug development pipeline using real-world data and advanced AI analytics451.

The collaboration provides Boehringer Ingelheim access to Tempus' de-identified database containing molecular, clinical, and imaging data, as well as its AI-powered analytics platform called Lens45.

Researchers can use the Lens platform to define or automatically generate patient cohorts for analysis, supporting work such as biomarker discovery, patient stratification, novel target identification, and development of combination therapy hypotheses5.

The partnership aims to integrate Tempus’ real-world patient data with Boehringer’s internal pre-clinical experimental data to accelerate the discovery and development of new cancer treatments, especially for hard-to-treat cancers45.

Tempus' database features over 8 million research records, significantly expanding the scope for data-driven insights in oncology research5.

Boehringer Ingelheim’s existing oncology drugs include Gilotrif (afatinib), Ofev (nintedanib), and Tevimbra (tislelizumab), and the company is pushing several investigational therapies through its pipeline5.

The partnership builds on previous work by Boehringer Ingelheim and Tempus, leveraging AI to enhance the precision and efficiency of drug research and development41.

Sources:

1. https://www.geneonline.com/boehringer-ingelheim-and-tempus-ai-partner-in-multi-year-collaboration-to-enhance-oncology-drug-development/

4. https://www.tempus.com/news/tempus-enters-multi-year-strategic-collaboration-with-boehringer-ingelheim-to-advance-its-cancer-pipeline/

5. https://community.hlth.com/insights/news/boehringer-ingelheim-enhances-oncology-research-through-tempus-ai-partnership-2025-05-15